Skip to main content
SpringerLink
Log in

Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Response to Comment

  • Letters to the Editor
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

The Original Article was published on 20 July 2017

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cohen H, Doré CJ, Clawson S, Hunt BJ, Isenberg D, Khamashta M, et al. Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. Lupus. 2015;24:1087–94. doi:10.1177/0961203315581207.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Green L, Lawrie AS, Patel S, Hossain F, Chitolie A, Mackie IJ, et al. The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation. Br J Haematol. 2010;151:469–76. doi:10.1111/j.1365-2141.2010.08433.x.

    Article  CAS  PubMed  Google Scholar 

  3. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573–9. doi:10.1161/CIRCULATIONAHA.111.029017.

    Article  CAS  PubMed  Google Scholar 

  4. Arachchillage DRJ, Efthymiou M, Mackie IJ, Lawrie AS, Machin SJ, Cohen H. Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism. Thromb Res. 2015;135:388–93. doi:10.1016/j.thromres.2014.11.037.

    Article  CAS  PubMed  Google Scholar 

  5. Zuily S, Regnault V, Guillemin F, Kaminsky P, Rat A-C, Lecompte T, et al. Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study. Thromb Res. 2013;132:e1–7. doi:10.1016/j.thromres.2013.04.012.

    Article  CAS  PubMed  Google Scholar 

  6. Pengo V, Ruffatti A, Legnani C, Testa S, Fierro T, Marongiu F, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011;118:4714–8. doi:10.1182/blood-2011-03-340232.

    Article  CAS  PubMed  Google Scholar 

  7. Erkan D, Zuily S, Banzato A, De Ceulaer K, Cohen H, Tektonidou M, et al. Antiphospholipid syndrome alliance for clinical trials and international networking clinical database and repository (“registry”) prospective follow-up analysis: one-year first and recurrent thrombosis risk. Arthritis Rheum. 2015;67

  8. Crowley MP, Cuadrado MJ, Hunt BJ. Catastrophic antiphospholipid syndrome on switching from warfarin to rivaroxaban. Thromb Res. 2017;153:37–9. doi:10.1016/j.thromres.2017.03.006.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases, CHRU de Nancy, Nancy, France

    Virginie Dufrost, Jessie Risse, Denis Wahl & Stéphane Zuily

  2. Inserm UMR_S 1116 at Lorraine University, Nancy, France

    Jessie Risse, Denis Wahl & Stéphane Zuily

Authors
  1. Virginie Dufrost
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jessie Risse
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Denis Wahl
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stéphane Zuily
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stéphane Zuily.

Ethics declarations

Funding

None.

Conflict of Interest

The authors declare that they have no conflict of interest.

Additional information

This reply refers to the comment available at http://dx.doi.org/10.1007/s11926-017-0675-3

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dufrost, V., Risse, J., Wahl, D. et al. Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Response to Comment. Curr Rheumatol Rep 19, 52 (2017). https://doi.org/10.1007/s11926-017-0676-2

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-017-0676-2

Keywords

Search

Navigation